Format
Sort by
Items per page

Send to

Choose Destination

Best matches for eculizumab aHUS:

Eculizumab in secondary atypical haemolytic uraemic syndrome. Cavero T et al. Nephrol Dial Transplant. (2017)

Eculizumab in Renal Transplantation: A 2017 Update. Grenda R et al. Ann Transplant. (2017)

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Noris M et al. Blood. (2014)

Search results

Items: 1 to 20 of 340

1.

Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.

Kello N, Khoury LE, Marder G, Furie R, Zapantis E, Horowitz DL.

Semin Arthritis Rheum. 2018 Dec 4. pii: S0049-0172(18)30493-1. doi: 10.1016/j.semarthrit.2018.11.005. [Epub ahead of print]

PMID:
30598332
2.

CHAPLE syndrome uncovers the primary role of complement in a familial form of Waldmann's disease.

Ozen A.

Immunol Rev. 2019 Jan;287(1):20-32. doi: 10.1111/imr.12715. Review.

PMID:
30565236
3.

Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.

Bianchi L, Gaiani F, Vincenzi F, Kayali S, Di Mario F, Leandro G, De' Angelis GL, Ruberto C.

Acta Biomed. 2018 Dec 17;89(9-S):153-157. doi: 10.23750/abm.v89i9-S.7911.

PMID:
30561409
4.

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion.

Portuguese AJ, Lipe B.

Blood Adv. 2018 Dec 11;2(23):3443-3446. doi: 10.1182/bloodadvances.2018027532. No abstract available.

5.

Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.

Merrill SA, Brodsky RA.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):371-376. doi: 10.1182/asheducation-2018.1.371. Review.

PMID:
30504334
6.
7.

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ.

Pediatr Nephrol. 2018 Nov 6. doi: 10.1007/s00467-018-4091-3. [Epub ahead of print] Review. Erratum in: Pediatr Nephrol. 2019 Jan 15;:.

PMID:
30402748
8.

Haploidentical Hematopoietic Stem Cell Transplant complicated by Atypical Hemolytic Uremic Syndrome and Kidney Transplant from the same donor with no Immunosuppression but C5 Inhibition.

Gianluigi A, Donata C, Fabio G, Francesco O, Francesco I, Francesca T, Antenore G, Piergiorgio M, Selena L, Daniele V, Silvana T, Massimo C, Fabio C.

Transplantation. 2018 Oct 26. doi: 10.1097/TP.0000000000002505. [Epub ahead of print]

PMID:
30365467
9.

An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment.

Medeni SS, Namdaroglu S, Cetintepe T, Ozlu C, Tasli F, Adibelli ZH, Bilgir O, Tatar E.

Hematol Rep. 2018 Sep 24;10(3):7553. doi: 10.4081/hr.2018.7553. eCollection 2018 Sep 5.

10.

Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment.

Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A.

Ther Apher Dial. 2018 Oct 8. doi: 10.1111/1744-9987.12763. [Epub ahead of print] Review.

PMID:
30294946
11.

Atypical hemolytic uremic syndrome: a new drug program and first Polish adult patient treated with eculizumab.

Ruszkowski J, Heleniak Z, Dębska-Ślizień A.

Pol Merkur Lekarski. 2018 Sep 21;45(267):119-121.

PMID:
30240381
12.

Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series.

Atrash S, Sasapu A, Pandey S, Cottler-Fox M, Motwani P.

Mayo Clin Proc Innov Qual Outcomes. 2017 Dec 20;2(1):69-73. doi: 10.1016/j.mayocpiqo.2017.11.004. eCollection 2018 Mar.

13.

Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.

Cao M, Leite BN, Ferreiro T, Calvo M, Fernández C, Alonso Á, Rodriguez A, Salvador P, Seijo R, Pita S, Arjona E, Rodríguez de Córdoba S, Valdés Cañedo F.

Am J Nephrol. 2018;48(3):225-233. doi: 10.1159/000492865. Epub 2018 Sep 11.

PMID:
30205388
14.

Eculizumab in pregnancy: a narrative overview.

Sarno L, Tufano A, Maruotti GM, Martinelli P, Balletta MM, Russo D.

J Nephrol. 2018 Aug 29. doi: 10.1007/s40620-018-0517-z. [Epub ahead of print] Review.

PMID:
30159857
15.

Nephromegaly in an infant with atypical hemolytic-uremic syndrome resolving successfully with eculizumab.

Kumar G.

Saudi J Kidney Dis Transpl. 2018 Jul-Aug;29(4):967-970. doi: 10.4103/1319-2442.239636.

16.

[Atypical hemolytic uremic syndrome].

Sepúlveda RA, Tagle R, Jara A.

Rev Med Chil. 2018 Jun;146(6):770-779. doi: 10.4067/s0034-98872018000600770. Review. Spanish.

17.

When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.

Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG.

Am J Nephrol. 2018;48(2):96-107. doi: 10.1159/000492033. Epub 2018 Aug 15.

18.

Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.

Walsh PR, Johnson S.

Pediatr Nephrol. 2018 Jul 30. doi: 10.1007/s00467-018-4025-0. [Epub ahead of print] Review.

PMID:
30058046
19.

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.

Clin Exp Nephrol. 2018 Jul 23. doi: 10.1007/s10157-018-1610-2. [Epub ahead of print]

PMID:
30039480
20.

Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.

Sridharan M, Go RS, Willrich MAV.

J Immunol Methods. 2018 Oct;461:15-22. doi: 10.1016/j.jim.2018.07.006. Epub 2018 Jul 19. Review.

PMID:
30031798

Supplemental Content

Loading ...
Support Center